-+ 0.00%
-+ 0.00%
-+ 0.00%

VolitionRX Announces Automated Nu.Q Cancer Test Detects 21 Cancer Types at High Specificity with Low False Positive Rate Among Healthy Patients; Potential for Use as Standalone Pan-Cancer Test or in Conjunction with Other Biopsy Technologies

Benzinga·03/21/2025 12:31:54
Listen to the news

Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificity

HENDERSON, Nev., March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in development detected a range of 21 different cancers. This could potentially be used as a standalone pan-cancer test or, given its low false positive rate among healthy people, be licensed out for use in conjunction with other liquid biopsy technologies to improve accuracy.